Australia Set To Approve Alexion’s Soliris For PBS Coverage
This article was originally published in PharmAsia News
Australia's Phamaceutical Benefits Advisory Scheme has recommended coverage of Soliris (eculizumab) for treating a rare blood disorder, with a final decision expected in November
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.